Alkermes plc (ALKS)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600
$45.90
+1.36 (+3.05%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 03)
$0.09 vs $-0.08 est.
Surprise +212.5%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 03, 2026Sep/2026$-0.08$0.09+212.5%

Our record of ALKS's reports since we began tracking; it grows each quarter.

Latest results, in brief

All ALKS 8-K briefs →
Nov 3, 8:09 AM ET

Alkermes Q3 revenue rises to $480.1 million; GAAP net income falls to $16.3 million

Mixed earnings 2.02

Alkermes reported third-quarter 2026 results on November 3, 2026. Total revenues rose to $480.1 million from $394.2 million a year earlier, but GAAP net income fell to $16.3 million from $82.8 million, and results included $29.8 million of costs related to the Avadel acquisition. The company reiterated its 2026 expectations, which call for total revenues of $1.73 billion to $1.84 billion and a GAAP net loss of $95 million to $115 million.

  • Q3 2026 total revenues were $480.1 million versus $394.2 million in Q3 2025; diluted EPS was $0.09 versus $0.49.
  • Q3 2026 Adjusted EBITDA was $120.1 million, compared with $121.5 million in Q3 2025.
  • Nine-month GAAP net loss was $49.7 million, compared with GAAP net income of $192.3 million in the same period of 2025.
  • 2026 expectations were reiterated, including a GAAP net loss of $95 million to $115 million and Adjusted EBITDA of $370 million to $410 million.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$480.13M+21.8% $0.09-81.6% $16.29M3.4%
Jun 2026$496.01M+27.0% $0.00-100.0% $501.00K0.1%
Mar 2026$392.91M+28.2% $-0.40-407.7% -$66.48M-16.9%
Dec 2025$384.55M-10.6% $0.29-66.7% $49.34M12.8%
Sep 2025$394.19M+4.2% $0.49-10.9% $82.76M21.0%
Jun 2025$390.66M-2.1% $0.52-1.9% $87.10M22.3%
Mar 2025$306.51M-12.5% $0.13-38.1% $22.46M7.3%
Dec 2024$429.99M+13.9% $0.87+27.9% $146.50M34.1%

From Alkermes plc's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$1.48B-5.2% $1.43-34.1%16.4%
FY2024$1.56B-6.4% $2.17+3.3%23.6%
FY2023$1.66B+49.6% $2.10—21.4%
FY2022$1.11B-5.3% $-0.97—-14.2%
FY2021$1.17B+13.0% $-0.29—-4.1%

Frequently asked questions

When is Alkermes's next earnings date?

Alkermes has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Alkermes earn last quarter?

For the quarter ended Sep 2026, Alkermes reported diluted EPS of $0.09 (-81.6% year over year) on revenue of $480.13M (+21.8%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.